The destruction of insulin-producing β-cells is the main pathophysiological feature of T1DM. Cell and gene therapy has always been thought to be able to recover eventually β-cell function, the ultimate means to cure diabetes. Ace Therapeutics can provide researchers engaged in cell and gene therapy of diabetes with more efficient function analysis and overall therapy services.

Mechanism of the suppressive action of T cell lymphocytes in T1DM (Ben-skowronek, I.; et al. International Journal of Molecular Sciences, 2021)

Gene Targets of T1DM

Two HLA class II haplotypes involved in antigen presentation, HLA-DR and HLA-DQ, are linked to approximately 50% of disease heritability.

Our Services

Cell and gene therapy research provides more options for diabetes treatment options. With the goal of scientific research of diabetes, Ace Therapeutics can provide a full set of services including stem cell therapy development service and gene therapy development service schemes. Our services include but not limited to the followings. 

• Target Prediction and Verification
  The mutation sites that lead to disease phenotypes are obtained through the Whole Genome Resequencing, and then relevant cell or animal models are constructed for verification.

Features of Our Services

Ace Therapeutics offers cost-effect and high-quality research services related to T1DM gene therapy for our clients worldwide. Our assays are developed and processed with the highest standard and the results are delivered on time without compromising quality. Please feel free to contact us.

Reference

1. Ben-skowronek, I.; et al. Potential Therapeutic Application of Regulatory T Cells in Diabetes Mellitus Type 1. International Journal of Molecular Sciences. 2021, 23(1), 390.

• T1DM Pathological Research Service
• T1DM Modeling Service
• T1DM Biomarker Development Service
• T1DM Diagnostic Development Services

• Mouse Models
• Assay Kits
• Antibodies
• Cell Lines & Lysates
• Proteins & Peptides
• Inhibitors & Activators